In April 2016, the Journal of the American Society of Nephrology (JASN) reported that PPIs --including Nexium-- may lead to an increased risk of kidney disease and kidney failure. Researchers said that people who take popular drugs such as Nexium are more likely to develop kidney failure and 28 percent more likely to develop chronic kidney disease, particularly if the drugs are taken for a long time.
Nexium Kidney Disease Studies
The study authors noted that these drugs are generally viewed as safe and may be overprescribed and continued for long periods without being necessary, Reuters Health reported.
Because Nexium is available over the counter, it is potentially more at risk of being overused than prescribed PPI medications.
In January 2016, a study published in JAMA Internal Medicine found a 20-50 percent increased risk of chronic kidney disease (CKD) associated with Nexium and other antacid drugs. The risk of a decline in kidney function was 32 percent higher for people taking PPIs and the risk of new cases of chronic kidney disease was 28 percent higher, according to Reuters Health. The JAMA study involved more than 20,000 people from national VA databases who recently took PPIs. This group was compared to almost the same amount of people who were taking H2 blockers. The study team concluded that people taking PPIs were at a much higher risk of new kidney problems than those people taking H2 blockers.
The JAMA study author said these studies indicate that patients should use PPIs only when medically necessary. Gastroenterologists are already cautious in prescribing PPIs, as they've been linked to other health problems, including bone fractures and an increased risk of intestinal infections such as Clostridium difficile infection, and pneumonia, Dr. Ziyad Al-Aly of the Clinical Epidemiology Center at the VA Saint Louis Health Care System, told CBS News. Dr. Morgan E. Grams, a kidney specialist at Johns Hopkins and another author of the JAMA study told CBS News that patients who require a long course of PPIs should routinely monitor their kidney function.
A study from the University of Copenhagen and published in Gastroenterology (July 2009) found that patients have almost impossible difficulties in stopping PPIs because the medications eventually cause the same problems they are supposed to treat. This phenomenon, called “rebound acid hypersecretion," can occur after taking prescription-strength PPI medication for just two months. Researchers concluded that this rebound effect can continue for up to three months after discontinuing the PPI.
Nexium kidney failure lawsuits have been filed against AstraZeneca, the Nexium manufacturer. Investigation has begun for hundreds of claimants who allege the heartburn drug and other PPIs have caused chronic kidney disease, acute kidney injury, acute interstitial nephritis, renal failure, and kidney failure.
Nexium Kidney Disease Lawsuits
Nexium patients claim that AstraZeneca failed to warn physicians and patients of the increased risks of kidney damage and renal failure. Further, if AstraZeneca had properly warned of the risks, patients would have chosen a different medication and/or would have had regular kidney function monitoring.
According to a British Study, published in the Journal of the American Medical Association (12/6), long-term use of Nexium or other proton pump inhibitors increases the risk of hip fractures in patients older than 50. Meanwhile, a 2010 study published in the Archives of Internal Medicine (5/10/10). found postmenopausal women taking proton pump inhibitors had a 25 percent higher chance of suffering a fracture, specifically, a spine or wrist fracture.
Nexium (known generically as esomeprazole magnesium) is in a class of drugs called proton pump inhibitors, which are used to treat gastro-esophageal reflux disease, stomach ulcers, duodenal ulcers and erosive esophagitis by reducing gastric acid levels in the stomach. It is made by AstraZeneca.
Proton Pump Inhibitor Side Effects
According to an announcement by the FDA in May 2010, the risks associated with prescription-strength Nexium and other proton pump inhibitors include a risk of bone fracture. That risk reportedly increases greatly if the drugs are being taken in high doses or for more than a year at a time. At the time, the FDA noted that the warning labels for the proton pump inhibitors would be updated to reflect that risk.
A year later, the FDA updated that warning to include information that high doses of proton pump inhibitors—including over-the-counter formulations—for more than a year is linked to an increased risk of osteoporosis and hip, wrist and spine fractures.
Of the studies the FDA relied on when making its decision, six found an increased risk of fractures in patients who used proton pump inhibitors, two suggested an increased risk of fractures with higher doses of the medications and two suggested an increased risk of fractures with longer duration of treatment. Most of the studies included in the FDA's review involved patients aged 50 or older.
According to reports, Nexium lawsuits have been filed against AstraZeneca, alleging patients suffered deterioration of their bones and fractures as a result of using Nexium.
Approximately 15 million people in the US alone are taking either over-the-counter or prescription PPI medications, according to CBS News. In 2013, Nexium was the second-best selling drug in the pharmaceutical industry, generating over $6.1 billion in sales worldwide for AstraZeneca, as reported by Medscape.
Nexium Side Effects Legal HelpIf you or a loved one has suffered damages or injuries from Nexium, please click the link below and your complaint will be sent to a Drug/Medical Device lawyer who may evaluate your claim at no cost or obligation.
Last updated on Apr-25-16